Iryna "Cheka" Tsybukh, combat medic, posthumously awarded title Hero of Ukraine
Iryna Tsybukh, a paramedic with the Hospitallers medical battalion, has been posthumously awarded the title of Hero of Ukraine.
Source: decree on the website of the Office of the President
Quote: "For personal courage and heroism displayed in the defence of state sovereignty and territorial integrity of Ukraine, selfless service to the Ukrainian people, I hereby decree:
Iryna Volodymyrivna Tsybukh, a public figure and a crew leader of the Hospitallers volunteer battalion, shall be bestowed the title of Hero of Ukraine and the Order of the Golden Star (posthumously)."
Read also: An interview with Iryna "Cheka" Tsybukh, combat medic, 1998-2024
Background:
In November 2023, Iryna "Cheka" Tsybukh was awarded the Order of Merit of III degree, and in March 2024, she became a laureate of the Ukrainska Pravda 100, The Power of Women award.
Six days before her death, in her last post on X (Twitter), Iryna wrote: "My birthday is coming soon, and I am proud to have lived to be 26". However, Iryna did not live to see her 26th birthday for two days. On 29 May, she was killed during a rotation in Kharkiv Oblast.
In June 2024, Zelensky posthumously conferred the Order of Courage of the III class on Iryna.
Support Ukrainska Pravda on Patreon!
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
5 days ago
- Newsweek
Parents Can Choose Genetic Makeup of Their Children With New IVF Option
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A U.S.-based biotech company has unveiled a new in vitro fertilization (IVF) option that allows parents to select embryos based on genetic markers tied to health and longevity. DNA testing and analysis company Nucleus Genomics has announced the world's first genetic optimization software that "helps parents pursuing IVF see and understand the complete genetic profile of each of their embryos." Why It Matters The company says it can analyze the genetic makeup of embryos to test for up to 900 conditions including diabetes, cancer, and heart disease. By choosing embryos with the lowest risk profiles, parents can theoretically boost their children's chances of living longer and healthier lives. But the practice also raises ethical concerns about choosing embryos based on probabilities. "Nucleus Embryo is the first-ever genetic optimization software that helps parents give their children the best possible start in life—long before they're even born," the company said on X, formerly Twitter. Composite image of a fetus and the brain. Composite image of a fetus and the brain. Getty/Newsweek What To Know Prospective parents can upload up to 20 embryo DNA files from their IVF clinics for over 900 genetic analyses spanning cancers, chronic conditions, appearance, cognitive ability, mental health, and other conditions. The company then provides clients with a detailed report, which shows their embryo's results. "Sort, compare, and choose your embryos based on what matters most to you," Nucleus Genomics said. Demo pictures of the process provided by the company shows that the tests will also reveal what eye color and hair color the child is likely to have. A screengrab from Nucleus Genomics showing an in vitro fertilization option that allows parents to select embryos based on genetic markers tied to health and longevity. A screengrab from Nucleus Genomics showing an in vitro fertilization option that allows parents to select embryos based on genetic markers tied to health and longevity. Nucleus Genomics It tests for markers for common conditions like type 2 diabetes, coronary artery disease, and high blood pressure, and genetic contributions to various cancers (e.g., breast, colorectal, ovarian). It also covers mental health risks, such as depression and anxiety disorders, as well as physical traits like eye color, hair color, height, BMI, and even IQ-related markers. The test offers a comprehensive genetic profile, allowing prospective parents to compare multiple embryos on these different attributes before choosing one for implantation. "Life span has dramatically increased in the last 150 years," Kian Sadeghi, the company's founder and chief executive, told the Wall Street Journal. "DNA testing to predict and reduce chronic disease can make it happen again." The 25-year-old told the Journal he sees no distinction between individuals using DNA tests to understand their own risks and those screening and ranking embryos to select one likely to live a longer life. "It is the same underlying motivation," Sadeghi said. "It is about living a longer, healthier life." "The longevity movement is about taking medicine back and putting it in the people's hands," Sadeghi added. "Why would that not apply now to the most intimate, personal, emotional, sensitive decision you will make? Picking your baby." A screengrab of analysis by Nucleus Genomics showing a detailed report of prospective embryo results. A screengrab of analysis by Nucleus Genomics showing a detailed report of prospective embryo results. Nucleus Genomics What People Are Saying Nucleus said on its website announcing Nucleus Embryo: "My parents are immigrants from Iran who came to America with nothing but a conviction that me and my siblings would have more. But when my 15-year-old cousin suddenly died in her sleep from a preventable genetic disease, my family was powerless to save her. "My parents, grieving the loss of my cousin, were also terrified. What if my siblings and I were at the same risk? That was the first time I understood what generational health meant. "Our users don't just do Nucleus for themselves—they do it for themselves and their loved ones. Now, I'm proud to say that care can start before a child is even born." Other users on social media questioned the ethics of the technology. One thread, viewed more than 3 million times, said, "Holy s***. It's happening…you don't just pick a child. You rank them by longevity potential." Emma Waters, a policy analyst at The Heritage Foundation, responded to tweets about the project. "'I only wanted you because you were a girl and the right kind of healthy. I destroyed the other 19 human embryos that your father and I created.' "Don't worry, it's 'not eugenics,' it's only science." 'I only wanted you because you were a girl and the right kind of healthy. I destroyed the other 19 human embryos that your father and I created.' Don't worry, it's 'not eugenics,' it's only science. — Emma Waters (@emlwaters) June 5, 2025 Asked for her definition of eugenics, she said, "The selection or rejection of a living human being based on certain traits or conditions. I.e., choosing which embryos live and which ones are destroyed based on factors like health, sex, and IQ." What Happens Next Polygenic embryo screening is largely unregulated in the U.S., and it is likely to remain that way for the foreseeable future.
Business Wire
5 days ago
- Business Wire
Scholar Rock to Participate in the 46 th Annual Goldman Sachs Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that David L. Hallal, Chief Executive Officer, and members of management will participate in a fireside chat at the 46 th Annual Goldman Sachs Global Healthcare Conference on Wednesday, June 11 at 9:20 a.m. ET in Miami, Florida. A live webcast of the events may be accessed by visiting the Investors & Media section of the Scholar Rock website at Archived replays of the webcasts will be available on the Company's website for approximately 90 days. About Scholar Rock Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily, the company is named for the visual resemblance of a scholar rock to protein structures. Over the past decade, Scholar Rock has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role. This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about our approach at and follow @ScholarRock and on LinkedIn. Scholar Rock® is a registered trademark of Scholar Rock, Inc. Availability of Other Information About Scholar Rock Investors and others should note that we communicate with our investors and the public using our company website including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly known as Twitter) and LinkedIn. The information that we post on our website or on X (formerly known as Twitter) or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Yahoo
5 days ago
- Yahoo
Russian strike kills 5 in Ukraine, including a 1 year old, hours after Trump-Putin call
KYIV, Ukraine (AP) — At least five people, including a 1-year-old child, his mother and grandmother, were killed Thursday in a nighttime Russian drone strike that hit the northern Ukrainian city of Pryluky, officials said. Six drones hit a residential area in the city at 5:30 a.m. local time, according to authorities. The child killed was the grandson of an emergency responder, Ukrainian President Volodymyr Zelenskyy said. 'One of the rescuers arrived to respond to the aftermath right at his own home,' Zelenskyy said in a post on Telegram. 'It turned out that a Shahed drone hit his house.' The attack came just hours after Donald Trump spoke by phone with Russian President Vladimir Putin. According to Trump, Putin said 'very strongly' that Russia will retaliate for Ukraine's weekend stunning drone attacks on Russian military airfields. Drones struck across regions Six people were wounded in the Pryluky attack and are in hospital, officials said. Pryluky, which had a prewar population of around 50,000 people, lies about 100 kilometers (60 miles) east of Kyiv, the capital. The city is far from the front line and does not contain any known military assets. Zelenskyy said a total of 103 drones and one ballistic missile targeted multiple Ukrainian regions overnight, including Donetsk, Kharkiv, Odesa, Sumy, Chernihiv, Dnipro and Kherson. 'This is another massive strike,' Zelenskyy said. 'It is yet another reason to impose the strongest possible sanctions and apply pressure collectively.' US peace effort remains stalled Zelenskyy, who has accepted a U.S. ceasefire proposal and offered to meet with Putin in an attempt to break the stalemate in negotiations, wants more international sanctions on Russia to force it to accept a settlement. Putin has shown no willingness to meet with Zelenskyy, however, and has indicated no readiness to compromise. U.S.-led diplomatic efforts to stop the more than 3-year-long war have delivered no significant progress, and the grinding war of attrition has continued unabated. Germany's new leader Friedrich Merz was due to meet with President Donald Trump in Washington on Thursday as he works to keep the U.S. on board with Western diplomatic and military support for Ukraine. Ukraine's top presidential aide, Andriy Yermak, met with senior American officials in Washington on Wednesday and called for greater U.S. pressure on Russia, accusing the Kremlin of deliberately stalling ceasefire talks and blocking progress toward peace, according to a statement on the presidential website. Yermak, who traveled to the U.S. as part of a Ukrainian delegation, met with senior American officials to bolster support for Ukraine's defense and humanitarian priorities. He said Ukraine urgently needs stronger air defense capabilities. More people wounded in Kharkiv Hours later, seventeen people were injured in a Russian drone strike on the eastern Ukrainian city of Kharkiv. Those hurt included children, a pregnant woman, and a 93-year-old woman, regional Gov. Oleh Syniehubov wrote on Telegram. At around 1:05 a.m., Shahed-type drones struck two apartment buildings in the city's Slobidskyi district, causing fires and destroying several private vehicles. 'By launching attacks while people sleep in their homes, the enemy once again confirms its tactic of insidious terror,' Syniehubov wrote on Telegram. Russian aircraft also dropped four powerful glide bombs on the southern city of Kherson, injuring at least three people, regional authorities said. ___ Follow AP's coverage of the war in Ukraine at Hanna Arhirova And Illia Novikov, The Associated Press
